Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 11, 2026

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

11.1K

HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.

Anjie Zhen1, Masakazu Kamata1, Valerie Rezek1

  • 1Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; UCLA AIDS Institute and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|June 9, 2015
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FcγR- and CD9-dependent synapse-engulfing microglia in the thalamus drive cognitive impairment following cortical brain damage in mice.

Nature communications·2026
Same author

Gut barrier integrity biomarkers are associated with increased inflammation and predict disease status in hospitalized COVID-19 patients.

Scientific reports·2026
Same author

Atomically Precise Polyanionic Boron Cluster Agents with Broad-Spectrum Antiviral Activity.

Precision chemistry·2026
Same author

Exploring the immune environment of glioblastoma in humanized mouse models.

Neuro-oncology·2026
Same author

Lentivirus-based HPSC therapy provides effective and long-term treatment in hypophosphatasia mouse model.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.

Journal of medicinal chemistry·2026

Developing enhanced immunity against human immunodeficiency virus (HIV) is crucial for long-term viral control. A novel stem cell-based gene therapy using a chimeric antigen receptor (CAR) shows promise in engineering HIV-resistant immune cells.

Area of Science:

  • Immunology
  • Gene Therapy
  • Virology

Background:

  • The human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte (CTL) response plays a vital role in controlling HIV infection.
  • Current immune responses are insufficient to eliminate HIV, necessitating strategies to enhance CTL activity for sustained viral suppression or eradication.

Purpose of the Study:

  • To investigate the potential of a protective chimeric antigen receptor (CAR) delivered via hematopoietic stem/progenitor cells (HSPCs) for engineering HIV immunity.
  • To assess the efficacy of CAR-modified HSPCs in generating functional, HIV-resistant immune cells capable of suppressing viral replication.

Main Methods:

  • Hematopoietic stem/progenitor cells (HSPCs) were engineered with a chimeric antigen receptor (CAR).
  • The differentiation potential and anti-HIV activity of CAR-modified HSPCs were evaluated in humanized mouse models.

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.7K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Related Experiment Videos

Last Updated: Apr 11, 2026

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

11.1K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.7K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
  • CAR-modified cells were assessed for resistance to HIV infection and their ability to suppress viral replication in vivo.

    • Main Results:

    • CAR-modified HSPCs successfully differentiated into functional T cells and natural killer (NK) cells in humanized mice.
    • These engineered immune cells demonstrated resistance to HIV infection.
    • The CAR-modified cells effectively suppressed HIV replication in vivo.

    Conclusions:

    • Stem cell-based gene therapy utilizing CAR-modified HSPCs is a feasible approach for enhancing HIV immunity.
    • This strategy holds potential for the effective treatment of chronic HIV infection and associated morbidities.
    • The engineered T and NK cells offer a promising avenue for long-term viral suppression or clearance.